Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Celularity inc - class a save search
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
Published: 2024-03-07 (Crawled : 14:30) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.0%
H: 27.91%
C: 27.67%
cancer cell tumor therapy
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
Published: 2023-05-19 (Crawled : 20:00) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
| Email alert
Add to watchlist
disease therapy
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Published: 2023-05-01 (Crawled : 20:00) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: -1.82%
H: 3.9%
C: 0.21%
presentation cell meeting therapy
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease
Published: 2023-01-06 (Crawled : 14:00) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.3%
H: 3.79%
C: -2.23%
disease therapy
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.3%
H: 3.79%
C: -2.23%
disease therapy phase 2b
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Published: 2022-11-10 (Crawled : 14:20) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 3.23%
H: 15.63%
C: 10.94%
cynk-101 preclinical immunotherapy meeting therapy
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
Published: 2022-07-27 (Crawled : 13:20) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.56%
H: 2.5%
C: -11.39%
cynk-101 treatment trial positive therapy her2- her2
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 4.73%
H: 5.21%
C: 3.47%
cynk-101 treatment fda drug drug designation cel orphan drug positive therapy cancer designation her2- her2
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 4.83%
H: 0.0%
C: -12.21%
cynk-101 fast track designation treatment fda fast track cel positive therapy cancer her2- her2
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 7.23%
H: 2.97%
C: -0.6%
cynk-001 fast track designation treatment fda fast track cel therapy designation aml
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: -1.42%
H: 0.0%
C: 0.0%
ema genetic preclinical therapy pre-clinical
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 1.48%
H: 2.19%
C: -2.19%
new drug fda clearance application drug fda clearance positive therapy cancer her2- her2
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: -1.8%
H: 0.0%
C: -4.22%
preclinical genetic immunotherapy therapy cancer pre-clinical
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.0%
H: 1.76%
C: 0.8%
ONCT | News | $8.6 -3.91% -1.82% 2.8K
|
Health Technology
|
| O: -5.66%
H: 2.5%
C: -1.75%
collaboration research therapy
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.0%
H: 1.76%
C: 0.8%
ONCT | News | $8.6 -3.91% -1.82% 2.8K
|
Health Technology
|
| O: -5.66%
H: 2.5%
C: -1.75%
collaboration research therapy
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Published: 2021-08-04 (Crawled : 00:00) - globenewswire.com
CELU | News F | $3.21 -3.02% -4.42% 42K
|
|
| O: 0.35%
H: 3.9%
C: -8.05%
treatment partnership immunotherapy solid tumors therapy t-cell car-t
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.